Prostate cancer drug shows promise for rare salivary gland tumors

NCT ID NCT05694819

First seen Apr 14, 2026 · Last updated May 09, 2026 · Updated 4 times

Summary

This study tested a drug called darolutamide, usually used for prostate cancer, in 57 people with a rare type of salivary gland cancer that has a specific protein (androgen receptor). The goal was to see if the drug could shrink tumors or slow the cancer's growth. Some participants received darolutamide alone, while others got it combined with another hormone-blocking drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chiba University Hospital

    Chiba, Chiba, 260-8677, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, 060-8648, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, 650-0017, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Fukuoka, 810-8563, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, 541-8567, Japan

  • The Jikei University Hospital

    Tokyo, Tokyo, 105-0003, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • Tokyo Medical And Dental University Hospital

    Tokyo, Tokyo, 113-8519, Japan

  • Tokyo Medical University Hospital

    Tokyo, Tokyo, 160-0023, Japan

  • Yokohama City University Hospital

    Yokohama, Kanagawa, 236-0004, Japan

Conditions

Explore the condition pages connected to this study.